Latest Biotech News

Bristol Myers Squibb joined Hengrui in a broad alliance that covers 13 drug programs, with deal value up to $15.2 billion. The pact reflects the deepening relationship between China-based large...

Roche agreed to acquire PathAI for $750 million upfront to expand AI-powered digital pathology capabilities for pathology laboratories and biopharma customers. PathAI’s technology is used to...

European regulators cleared Fractyl Health for a clinical trial of its GLP-1 gene therapy candidate, positioning the company in the race to replace chronic GLP-1 injections and pills with a...

Capsida Biotherapeutics said it still has no answers after investigating the death of a child in its gene therapy trial of CAP-002 last September. The company said progress has been stymied...

Partner Therapeutics said its bispecific antibody Bizengri received FDA approval for advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. The therapy was acquired as U.S. rights from...

enGene’s stock plunged after updated Phase II results for its nonviral gene therapy candidate detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The update...

Knit Health, a UC Berkeley spinout, raised $11.6 million in seed funding to pursue an AI-driven approach to healthcare operations described as thinking “like a doctor.” The company’s strategy...

Nuclera launched an antibody screening service to streamline the transition from antibody hit generation to lead selection, aiming to reduce the experimental bottleneck that slows AI-driven...

Partner Therapeutics’ Bizengri (bispecific antibody targeting NRG1 fusions) received FDA approval for advanced cholangiocarcinoma driven by NRG1 gene fusions. The approval makes Bizengri the first...

Bristol Myers Squibb struck a broad, multi-asset partnership with China’s Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs spanning the two companies’ pipelines. The...

ASGCT highlighted strategies to address AAV’s long-standing “one-and-done” limitation, focusing on redosing approaches and overcoming pre-existing immunity that can blunt subsequent...

enGene’s Phase II LEGEND interim updates for detalimogene voraplasmid delivered a deterioration versus earlier expectations, triggering a sharp investor selloff. The updated data showed complete...

AbCellera reported Phase 1 data for ABCL635, adding new evidence for the company’s pipeline momentum as it advances its antibody-development platform. While the excerpt does not provide outcome...

GSK took rights to a cardiovascular siRNA program from China-based SiranBio, targeting ALK7. The agreement covers most global rights but excludes mainland China, Hong Kong, Macau and Taiwan, where...

European regulators cleared Fractyl Health’s clinical test of a GLP-1 gene therapy, placing the company at the center of the race to deliver “one-and-done” alternatives to chronic GLP-1 injections...

Roche agreed to acquire PathAI in a deal valued at $750 million upfront, aiming to strengthen AI-powered digital pathology capabilities used by pathology labs and biopharma customers. The...

MBX Biosciences drew investor attention after preliminary Phase 1 data suggested efficacy and tolerability for its monthly obesity drug MBX-4291, a GLP-1/GIP co-agonist prodrug. The company...

Windward Bio secured $165 million for clinical trials targeting respiratory diseases, according to the company’s financing announcement. The round will support a lead program in respiratory...

Bristol Myers Squibb moved deeper into China’s oncology R&D ecosystem by signing a broad partnership with Hengrui Pharma, agreeing to pay $600 million upfront for 13 early-stage programs spanning...

Partner Therapeutics secured its first FDA approval with Bizengri, a bispecific antibody for advanced cholangiocarcinoma driven by NRG1 gene fusions. The approval adds a new targeted option for a...